<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651326</url>
  </required_header>
  <id_info>
    <org_study_id>PR12</org_study_id>
    <secondary_id>CAN-NCIC-PR12</secondary_id>
    <secondary_id>CDR0000589247</secondary_id>
    <nct_id>NCT00651326</nct_id>
  </id_info>
  <brief_title>Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer</brief_title>
  <acronym>DART</acronym>
  <official_title>A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such&#xD;
      as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of&#xD;
      androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. It is not yet&#xD;
      known whether giving androgen suppression therapy together with radiation therapy is more&#xD;
      effective with or without docetaxel in treating prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying androgen suppression therapy, radiation&#xD;
      therapy, and docetaxel to see how well they work compared with androgen suppression therapy&#xD;
      and radiation therapy in treating patients with high-risk localized prostate cancer.&#xD;
&#xD;
      CLOSURE: This trial closed to further accrual in November 2009. The study endpoints will not&#xD;
      be reached.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare disease-free survival rates in patients with high-risk localized&#xD;
           adenocarcinoma of the prostate treated with androgen suppression therapy and&#xD;
           radiotherapy with vs without docetaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare overall survival.&#xD;
&#xD;
        -  To compare time to biochemical disease progression.&#xD;
&#xD;
        -  To compare time to local disease progression.&#xD;
&#xD;
        -  To compare time to distant disease progression.&#xD;
&#xD;
        -  To compare time to next anticancer therapy.&#xD;
&#xD;
        -  To compare progression-free survival.&#xD;
&#xD;
        -  To compare degree of prostate-specific antigen (PSA) suppression prior to radiotherapy.&#xD;
&#xD;
        -  To compare quality of life (QOL) using EORTC QLQ C30 and EORTC QLQ PR25 questionnaires&#xD;
           and a trial-specific checklist.&#xD;
&#xD;
        -  To compare the nature, severity, and frequency of adverse events.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≤ 7&#xD;
      vs ≥ 8), baseline prostate-specific antigen (PSA) (&gt; 20 ng/mL vs ≤ 20 ng/mL), and&#xD;
      participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive androgen suppression therapy comprising oral flutamide three&#xD;
           times daily or oral bicalutamide once daily for 4 weeks AND leuprolide subcutaneously&#xD;
           (SC) or intramuscularly every 1-6 months, buserelin SC every 2 or 3 months, or goserelin&#xD;
           SC every 1 or 3 months for 3 years. Patients also receive docetaxel IV over 60 minutes&#xD;
           on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses. Beginning&#xD;
           at least 4 weeks after completion of chemotherapy, patients undergo pelvic radiotherapy&#xD;
           once daily 5 days a week for up to 8 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive androgen suppression therapy and undergo pelvic radiotherapy as&#xD;
           in arm I.&#xD;
&#xD;
      Patients complete quality of life questionnaires at baseline, periodically during treatment,&#xD;
      and then every 6 months for 5 years.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 and 6 months, every 6 months&#xD;
      for 5 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">March 3, 2008</start_date>
  <completion_date type="Actual">January 18, 2011</completion_date>
  <primary_completion_date type="Actual">May 14, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next anti-cancer therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of prostate-specific antigen (PSA) suppression prior to radiotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>46 Gy in 23 fractions over &lt; 5 weeks.&#xD;
Boost:&#xD;
24-28 Gy in 12-14 fractions over &lt; 3 weeks</description>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
    <arm_group_label>Antiandrogen; LHRH; Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Antiandrogen; LHRH; Docetaxel, Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Localized (N0, M0) disease&#xD;
&#xD;
               -  No small cell or transitional cell carcinoma in the biopsy specimen&#xD;
&#xD;
          -  Considered to be at high risk for recurrence based on the presence of at least one of&#xD;
             the following adverse prognostic features:&#xD;
&#xD;
               -  T stage ≥ 3a&#xD;
&#xD;
               -  Gleason score ≥ 8&#xD;
&#xD;
               -  Baseline prostate-specific antigen (PSA) &gt; 20 ng/mL&#xD;
&#xD;
          -  Deemed to be an appropriate candidate for chemotherapy, as assessed by a medical&#xD;
             oncologist&#xD;
&#xD;
          -  Negative pelvic and para-aortic lymph nodes on CT scan or MRI of the abdomen and&#xD;
             pelvis&#xD;
&#xD;
               -  Any lymph node appearing ≥ 1.5 cm on CT scan or MRI must be histologically&#xD;
                  negative by either needle aspirate or lymph node dissection&#xD;
&#xD;
          -  No metastases by chest x-ray and bone scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  AST and/or ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Able (i.e., sufficiently fluent) and willing to complete the quality of life&#xD;
             questionnaires in either English or French&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer or&#xD;
             other curatively treated solid tumor with no evidence of disease for &gt; 5 years&#xD;
&#xD;
          -  No serious non-malignant disease resulting in a life expectancy of &lt; 10 years&#xD;
&#xD;
          -  No known hypersensitivity to any study medications&#xD;
&#xD;
          -  No existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No bilateral hip replacement prostheses&#xD;
&#xD;
          -  No contraindication to pelvic radiotherapy including, but not limited to, inflammatory&#xD;
             bowel disease or severe bladder irritability&#xD;
&#xD;
          -  No medical condition that would contraindicate the study treatment regimen, including&#xD;
             severe respiratory insufficiency, uncontrolled diabetes, or severe hypertension&#xD;
&#xD;
          -  No other serious illness or psychiatric or medical condition that would preclude&#xD;
             management of the patient according to the study, including active uncontrolled&#xD;
             infection or significant cardiac dysfunction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior androgen suppression therapy allowed provided it was initiated no more than 4&#xD;
             weeks prior to study entry&#xD;
&#xD;
          -  At least 4 weeks since prior 5-alpha-reductase inhibitors (e.g., finasteride) for&#xD;
             benign prostatic hypertrophy&#xD;
&#xD;
          -  No prior cytotoxic anticancer therapy&#xD;
&#xD;
          -  No prior chemotherapy for carcinoma of the prostate&#xD;
&#xD;
          -  No prior surgical treatment for carcinoma of the prostate, except transurethral&#xD;
             resection or bilateral orchiectomy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No concurrent nilutamide&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy (cytotoxic therapy, biologic/immunotherapy, or&#xD;
             radiotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. McKenzie, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim N. Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

